Cameron Turtle, CEO of Spyre Therapeutics,Inc. speaks with Venrock partner Nimish Shah about Spyre’s priorities for 2025, building a collaborative and productive Board, how culture shines through when the going gets tough, and the best advice he's ever received. 

This podcast was recorded in December 2024. Please be advised that comments made during this podcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Spyre Therapeutic, Inc.'s (“Spyre”) expectations regarding Spyre’s product candidates including their potential safety and efficacy, business and clinical trial plans, milestones and timelines. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to Spyre's SEC filings, including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q. These forward-looking statements are only as of the date they were made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.

Bruce Perkins, healthcare advisor and former Humana leader, speaks with Venrock partners Bryan Roberts and Bob Kocher about how he built Humana into a juggernaut of Medicare Advantage and his prognostications for the industry amid CMS-HCC model version 28, GLP-1s, margin structure recovery, and ongoing drug price negotiations.

Bob Kocher and Bryan Roberts take the mic for a special episode highlighting their predictions for healthcare in 2025. They go deeper on their thoughts about Medicare Advantage under the new administration, how a resurgence of IPOs and M&A could play out, where Big Tech may actually be good at healthcare, and more. To read all 10 of their annual predictions, check out their article in Fortune Magazine.

Ashish Jha, Dean of Brown University’s School of Public Health, speaks with Venrock partners Bryan Roberts and Bob Kocher about the chapters of his career in public health before, during, and after the pandemic. He shares what he got right and wrong during his time as White House COVID-19 coordinator, how he managed 40-50 media interviews a day, where we have work to do on public health issues, and more. 

Elizabeth Pemmerl, Chief Revenue Officer at GitHub, speaks with Venrock partner Ethan Batraski to discuss her nearly decade-long journey with GitHub. Pemmerl shares how she transitioned from working in the public sector to GitHub, go-to-market strategies, balancing developer vs. enterprise needs, changing developer behavior and more. 

David Stark, Chief Medical Officer at Morgan Stanley, speaks with Venrock partner Bob Kocher to discuss his career journey from practicing medicine to taking a non-clinical role in business. Stark shares how he views his role as Chief Medical Officer, advice for other doctors who want to transition out of practicing medicine, what he’s proudest of at Morgan Stanley and more.

Alex Rosemblat, former Chief Marketing Officer at Datadog, speaks with Venrock partner Ethan Batraski to discuss his 11-year run at the helm of Datadog’s Marketing Team and what’s next for his career. Rosemblat shares insights into leading Datadog’s go-to-market strategy, advice for other marketing leaders tackling this for a new product or company for the first time, his biggest learning from Datadog and more. During the conversation, Rosemblat recommended Digital CMO's Guide to Marketing Measurement by Bryan Semple. 

Book mentioned: https://vnrk.co/3VuFvxg 

Heather Turner, CEO at Carmot Therapeutics, speaks with Venrock partner Nimish Shah to discuss her time as CEO. Turner shares how she guided the company through its acquisition by Roche, advice for other CEOs on the verge of an acquisition, her perspective on the GLP-1 market and what excites her about the future of biotech. 

Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.

We have a special episode today because Venrock’s 8th annual Healthcare Prognosis results are in! From drugs (e.g., GLP-1s, pricing negotiations) to fundraising and optimism around the equity market to cybersecurity and AI regulations - this year’s survey covers it all. In this episode, partners Bryan Roberts and Bob Kocher sit down to share their perspectives on the most interesting findings.